Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: Effects on tissue retention in vivo

被引:15
作者
Huang, Bao-Cheng
Davern, Sandra
Kennel, Stephen J.
机构
[1] Univ Tennessee, Grad Sch Med Res, Knoxville, TN 37920 USA
[2] Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA
关键词
laminin; scFv; diabody; binding constant; tumor;
D O I
10.1016/j.jim.2006.04.006
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Phage display techniques identified a scFv, 15-9, which binds to murine laminin-1 and accumulated selectively in tumors. In this study, a covalent diabody was constructed by changing the amino acid residues at positions VH44 and VL100 to cysteine residues so that the diabody form could be stabilized via a disulfide bond. The covalent diabody was expressed in Pichiapastoris and purified by affinity chromatography. The binding properties were measured by surface plasmon resonance and solid phase binding of 1 25 1 diabody and scFv. Data from the plasmon resonance method yielded calculated K-DS of 4.4 x 10(-10) M for the covalent diabody and 9.9 x 10(-8) M for the scFv Kos calculated from solid phase binding of radioiodinated proteins were 1.7-2.1 x 10(-10) M and 2.1-2.4 x 10(-8) M respectively. The rate of dissociation of 125, scFv from solid phase laminin was independent of laminin concentration; however, the dissociation of the 125 1 diabody was dependent both on the concentration of laminin and on the concentration of the diabody. Specifically, high concentrations of laminin yielded very slow rates of diabody dissociation indicating that bivalent attachments had formed. When higher amounts of diabody were used that essentially saturated the laminin sites with univalent binding, the dissociation rate was similar to that for the scFv indicating univalent binding. Biodistribution studies in tumor-bearing SCID mice showed that the covalent diabody improved the ratio of tumor/muscle 2 fold over that obtained with the scFv, although the absolute amount of protein bound to the tumor site was not significantly different for the two forms. The data also showed that retention of the diabody in the tumor and kidney, sites where laminin is present in high concentration, was much longer compared to that of scFv. These data are consistent with the hypothesis that both scFv and diabody forms bind to available laminin in vivo with similar association kinetics, but that in situations of high target concentration, the diabody can bind bivalently and is thus retained at the binding site much longer than the scFv. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:149 / 160
页数:12
相关论文
共 43 条
[31]  
Pavlinkova G, 1999, J NUCL MED, V40, P1536
[32]   CRYSTAL-STRUCTURE OF A DIABODY, A BIVALENT ANTIBODY FRAGMENT [J].
PERISIC, O ;
WEBB, PA ;
HOLLIGER, P ;
WINTER, G ;
WILLIAMS, RL .
STRUCTURE, 1994, 2 (12) :1217-1226
[33]   STABILIZATION OF THE FV FRAGMENTS IN RECOMBINANT IMMUNOTOXINS BY DISULFIDE BONDS ENGINEERED INTO CONSERVED FRAMEWORK REGIONS [J].
REITER, Y ;
BRINKMANN, U ;
KREITMAN, RJ ;
JUNG, SH ;
LEE, B ;
PASTAN, I .
BIOCHEMISTRY, 1994, 33 (18) :5451-5459
[34]   Disulfide stabilization of antibody Fv: Computer predictions and experimental evaluation [J].
Reiter, Y ;
Brinkmann, U ;
Jung, SH ;
Pastan, I ;
Lee, B .
PROTEIN ENGINEERING, 1995, 8 (12) :1323-1331
[35]   Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments [J].
Reiter, Y ;
Brinkmann, U ;
Lee, BK ;
Pastan, I .
NATURE BIOTECHNOLOGY, 1996, 14 (10) :1239-1245
[36]   Generation and characterization of recombinant human antibodies specific for native laminin epitopes:: potential application in cancer therapy [J].
Sanz, L ;
Kristensen, P ;
Russell, SJ ;
García, JRR ;
Alvarez-Vallina, L .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (10) :557-565
[37]   Unexpected observation of concentration-dependent dissociation rates for antibody-antigen complexes and other macromolecular complexes in competition experiments [J].
Scheuermann, J ;
Viti, F ;
Neri, D .
JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 276 (1-2) :129-134
[38]  
TERZAGHI M, 1978, CANCER RES, V38, P4546
[39]  
Viti F, 1999, CANCER RES, V59, P347
[40]   The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs [J].
Wittel, UA ;
Jain, M ;
Goel, A ;
Chauhan, SC ;
Colcher, D ;
Batra, SK .
NUCLEAR MEDICINE AND BIOLOGY, 2005, 32 (02) :157-164